Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes

Aim: To assess long-term safety and efficacy of empagliflozin as add-on to metformin plus sulphonylurea versus placebo in patients with type 2 diabetes. Methods: Of 666 patients treated with empagliflozin 10 mg, empagliflozin 25 mg or placebo in a 24-week study (EMPA-REG METSUTM), 71.2% continued in a Phase III double-blind extension trial (EMPA-REG EXTEND™ METSU) for ≥52 weeks (until the last person had been treated for 76 weeks). Exploratory efficacy endpoints were changes from baseline (of EMPA-REG METSUTM) in HbA1c and body weight at week 76. Results: At baseline, mean HbA1c (%) was 8.15, 8.07, 8.10 and mean…